←
Derek Abbott1,039 posts
Derek Abbott avatar

Derek Abbott

@inflammgenetics

Cecil and Ida Green Chair of Immunology and Genomic Medicine. National Jewish Health. Physician Scientist target hunting in inflammation. Views are my own.

◷ Joined May 2013▧ 175 Photos and videos
Derek Abbott avatar
Derek Abbott@inflammgenetics·Aug 4

I'm very excited to announce two big developments in the Dept. of Immunology and Genomic Medicine @NJHealth. First, we welcome the first faculty member of our expansion - Jaime Barr! Second, we thank the Theodore and Maxine Munick family for a $10M investment in our growth!

Post attachmentPost attachment
Matt Kaeberlein avatar
⟳ Derek Abbott retweeted
Matt Kaeberlein@mkaeberlein·Jun 8

Pretty interesting story in @ScienceMagazine this week on what looks like a serious problem in the senescence field. More than 400 papers apparently used the wrong antibody for p16-INK4a — an antibody that actually recognizes a completely different, unrelated protein (a component of the actin cytoskeleton). This affects work on senescent cell accumulation in aging and disease, and most critically, some of the evidence base for senolytic drug research. What concerns me most is that many of these papers somehow got the "right" answer using the wrong antibody. That's not just an innocent reagent mix-up — it raises real questions about data fabrication or selective reporting in at least some of these labs. I've commented before about how ignoring data that doesn't fit the narrative is a major problem in certain areas of the longevity literature (e.g. sirtuins and NAD), and here a potentially widespread example in senescence. Hopefully journals will investigate and retract as necessary, but based on my experience that seems optimistic. One concrete fix is that journals should flag problematic antibody product codes at submission so reviewers can catch this before publication. Reviewers should absolutely be on the lookout for this going forward. However, these fixes won't address the larger problem. We need to understand how these scientists got the results they wanted and published them over 400 times (!!!): whether through intentional deception, incompetence, accident, or some legitimate explanation. Credit for discovering this goes to @addictedtoigno1 who wrote about it first on his blog: For Better Science science.org/content/article/…?

Catharine avatar
⟳ Derek Abbott retweeted
Catharine@DrCatharineY·May 27

In case you still think there is any normalcy in how scientists are being treated at NIH. Photo credit: 27UNIHTED

Post attachment
Rep. Jake Auchincloss 🟧 avatar
⟳ Derek Abbott retweeted
Rep. Jake Auchincloss 🟧@RepAuchincloss·May 19

Asked mid-season about the Yankees, former Red Sox General Manager Theo Epstein once said that he had looked at their roster at the start of the season, realized that they'd win 100 games, and now ignored their weekly standings in order to focus on his own roster's ability to compete. I raised this anecdote at a recent roundtable of experts discussing China's rise in biotechnology. China is uplifting scientists, investing hundreds of billions in R&D, and accelerating clinical trials. It's going to win 100 games. The center of biomedical gravity is moving to China from America, just like it moved from Europe to America at the close of last century. Unless America decides to win 110 games. statnews.com/2026/05/18/biot…

Derek Abbott avatar
Derek Abbott@inflammgenetics·Mar 20

Drug targeting human MLKL might focus on preventing the release of the 4-Helix bundle rather than preventing MLKL phosphorylation. 4/4

Derek Abbott avatar
Derek Abbott@inflammgenetics·Mar 20

MLKL prevents further kinase activity of RIPK3 beyond the initial auto-phosphorylation at sites 224 and 227. In humans, Michelle's work shows that the key initiating event in MLKL activation is not phosphorylation but rather a flipping of the 4-helix bundle of MLKL. 3/4

Derek Abbott avatar
Derek Abbott@inflammgenetics·Mar 20

While phosphorylation is key in mouse necroptosis, human necroptosis shows a key biochemical difference. Phosphomimetic mutations on MLKL are not sufficient for necroptosis. In fact, in the human system, RIPK3 and MLKL are basally bound together. 2/3

Derek Abbott avatar
Derek Abbott@inflammgenetics·Mar 20

CWRU MSTPstudent Michelle Pan's dissertation is now available online. In this work, Michelle challenged the idea that, in human necroptosis, RIPK3 phosphorylation of MLKL is the main pore-initiating event. 1/3 cell.com/cell-reports/fullte…

Derek Abbott avatar
Derek Abbott@inflammgenetics·Mar 12

Excited for ⁦@cwrumstp⁩ and new Abbott lab alum, Michelle Pan, to defend her dissertation today! Congratulations to Dr Pan. Look out for her paper coming out in a couple of weeks!

Post attachmentPost attachmentPost attachment
Derek Abbott avatar
Derek Abbott@inflammgenetics·Mar 10

This weekend, my wife and I were very excited to attend our first Beaux Arts Ball at National Jewish Health. Its very inspiring to work at an institution dedicated to finding treatments and cures for immunologic diseases and to work with such a dedicated team. @KathrynTeng

Post attachment
Derek Abbott avatar
Derek Abbott@inflammgenetics·Jan 26

Pleased to share a new review article focusing on Gasdermin D's role in Pathology spearheaded by Bowen Zhou, a former @cwrumstp student and current Pathology fellow @UHhospitals annualreviews.org/content/jo…

Vijay Rathinam avatar
⟳ Derek Abbott retweeted
Vijay Rathinam@RathinamVA·Jan 15

Shiga toxin-induced cell death—the underlying cause of a potentially fatal renal disease in children—occurs via pyroptosis, not apoptosis as previously thought, and is driven by an intriguing NLRP1->Caspase-3-> gasdermin E pathway. Congrats to Priya's lab! pnas.org/doi/10.1073/pnas.25…

Post attachment
Derek Abbott avatar
Derek Abbott@inflammgenetics·13 Dec 2025

This isn’t the case at National Jewish Health. We are actively hiring to expand our tenure track faculty in Immunology and genomic medicine. linkedin.com/pulse/pulling-u…